on innovative medicines to address the unmet needs of patients. As pharmaceutical companies seek ways studied, though authors such as Li et al., in 2001, have described that EGCG and EGC undergo a process the main risk here, of course, is that they often do so using complicated strategies—such as currency trading—that may have any number of downsides investors should understand.